Last update:
Medications news
Medications
FDA approves Zoryve for atopic dermatitis
The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) cream, 0.15%, for the treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients (ages 6 years and older).
13 hours ago
0
1
Medications
Study reveals underuse of a key drug in patients with treatment-resistant schizophrenia
The Psychiatry and Mental Health research group at the Germans Trias i Pujol Research Institute (IGTP), together with the ETEP (Study and Treatment of Psychotic Episodes) group at Hospital del Mar, has published a study in ...
Jul 11, 2024
0
0
Black and Hispanic women receive lower doses of postpartum pain medication, finds study
Inequities in pain medication treatment received postpartum, after giving birth, were found in a Cedars-Sinai study of 18,000 women. The disparities were observed even among patients reporting the highest pain levels.
Jul 11, 2024
0
0
Only 1 in 4 still taking Ozempic, Wegovy for weight loss two years later
Three of four patients stop taking Ozempic or Wegovy two years after being prescribed the blockbuster drugs for weight loss, a new analysis shows.
Jul 11, 2024
0
0
Study finds missed opportunities with COVID antivirals on Australian Pharmaceutical Benefits Scheme
A new study has revealed significant discrepancies in the prescription of COVID-19 antivirals, indicating that many patients may not have received the most effective treatment available.
Jul 11, 2024
0
0
New medication for stress urinary incontinence? Investigational drug shows promise
An investigational medication designated TAS-303 shows efficacy and safety in treatment of women with stress urinary incontinence (SUI), reports a placebo-controlled clinical trial in the August issue of The Journal of Urology.
Jul 11, 2024
0
0
Blood cancer drug could make radiotherapy on brain tumors more effective
Drugs developed to fight blood and other cancers could also help improve the efficiency of radiotherapy in the most commonly diagnosed low-grade brain tumor in adults, a new study has found.
Jul 10, 2024
0
0
A drug that lowers blood lipids could treat the world's most common liver disease
The University of Barcelona has led a study that suggests using the drug known as pemafibrate to treat liver disease associated with metabolic disorders, the most common liver pathology in the world, which affects 1 in 4 ...
Jul 10, 2024
0
0
Safety of generic Viagra, other drugs called into doubt after false data found by FDA
Generic versions of erectile dysfunction drugs Viagra and Cialis, among other medications, were allowed on the U.S. market using potentially problematic data that call into question their safety and efficacy, a Bloomberg ...
Jul 10, 2024
0
2
Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers: Study
A new research paper was published in Oncotarget titled, "Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling ...
Jul 9, 2024
0
0
Experts weigh in on new generation of weight loss medications
We've all seen the ads and read about celebrities who have successfully lost weight using one of the new weight loss medications like Ozempic, Wegovy and Zepbound that have exploded in popularity over the past year.
Jul 9, 2024
0
0
Q&A: Researchers find adverse drug events are frequent and many are preventable in the outpatient setting
Rachel L. Wasserman, PharmD, of the Department of General Internal Medicine at Brigham and Women's Hospital, is the lead author and David W. Bates, MD, medical director of Clinical and Quality Analysis for Mass General Brigham ...
Jul 9, 2024
0
0
1999 to mid-2000s saw increase in seniors using prescription meds
From 1999 to the mid-2000s, the proportion of U.S. adults aged 65 years or older who used prescription medications increased, according to a research letter published online July 1 in JAMA Internal Medicine.
Jul 9, 2024
0
0
Study compares rivaroxaban, warfarin with apixaban for cirrhosis, atrial fibrillation
For patients with cirrhosis and nonvalvular atrial fibrillation (AF), initiators of rivaroxaban or warfarin versus apixaban have significantly higher rates of major hemorrhage, according to a study published online July 9 ...
Jul 9, 2024
0
0
South Africa drops probe of J&J after it agrees to lower price of TB drug and withdraws patent
Medical advocacy groups welcomed Johnson & Johnson's decision not to enforce its patent on a critical tuberculosis medication, allowing its production at much lower prices, after South African authorities opened an investigation ...
Jul 9, 2024
0
4
Seven-day buprenorphine is safe for those with minimal opioid withdrawal, study shows
A seven-day, extended-release version of buprenorphine—a treatment for opioid use disorder (OUD) that can reduce opioid use and overdose deaths—is safe and effective for people with OUD experiencing minimal symptoms of ...
Jul 8, 2024
0
0
Mounjaro outperforms Ozempic for weight loss, finds study
Mounjaro outperforms Ozempic in helping people lose weight, a new study shows.
Jul 8, 2024
0
17
Older weight loss drugs are in demand. But are they safe or effective? And should you take them?
With Ozempic-type weight loss drugs in short supply, more people are turning to old-school weight loss drugs such as Qsymia and Contrave, which come in pill form but also include serious warning labels.
Jul 8, 2024
0
0
Indigenous people can get cheap or free medicines, but researchers show access depends on your postcode
Policies designed to ensure Indigenous Australians have equitable access to medicines aren't being accessed uniformly across the nation, our research shows.
Jul 8, 2024
1
0
Novel treatment improves embryo implantation and live birth rates in infertile women undergoing IVF and ICSI
New research has demonstrated the effectiveness of a first-in-class oral, non-hormonal drug in increasing embryo implantation, pregnancy and live birth rates among infertile women who are undergoing in vitro fertilization ...
Jul 7, 2024
1
15
